Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ANPEP | P15144 | 3/20 | 0.41 |
| ▸ | ENPEP | Q07075 | 2/20 | 0.41 |
| ▸ | GPR88 | Q9GZN0 | 1/20 | 0.36 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3591156 | 1.00 | ANPEP (0.41) | ANPEPENPEPGPR88ALOX5 | |
| SCHEMBL3608680 | 0.87 | ANPEP (0.41) | ANPEPENPEPGPR88ALOX5 | |
| SCHEMBL3588545 | 0.87 | ANPEP (0.40) | ANPEPENPEPGPR88ALOX5 | |
| SCHEMBL3614943 | 0.87 | ANPEP (0.40) | ANPEPENPEPGPR88ALOX5 | |
| SCHEMBL3588546 | 0.87 | ANPEP (0.40) | ANPEPENPEPGPR88ALOX5 | |
| SCHEMBL3604142 | 0.86 | ANPEP (0.41) | ANPEPENPEPGPR88ALOX5 | |
| SCHEMBL3597706 | 0.86 | ANPEP (0.41) | ANPEPENPEPGPR88ALOX5 | |
| SCHEMBL3597709 | 0.86 | ANPEP (0.41) | ANPEPENPEPGPR88ALOX5 | |
| SCHEMBL3607510 | 0.85 | GPR88 (0.41) | ANPEPENPEPGPR88ALOX5 | |
| SCHEMBL3338710 | 0.85 | GPR88 (0.41) | ANPEPENPEPGPR88ALOX5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8487108-B2 | Piperidinyl carbamate intermediates for the synthesis of aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-8455521-B2 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2013-06-04 | — | — | US | disclosed |
| EP-1966139-B1 | ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS INC (US) | 2011-12-21 | — | — | EP | disclosed |
| US-7754737-B2 | Diaminoalkane aspartic protease inhibitors | VITAE PHARMACEUTICALS, INC. (US) | 2010-07-13 | — | — | US | disclosed |
| US-20100048636-A1 | Aspartic Protease Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-02-25 | — | — | US | disclosed |
| US-20090018103-A1 | Diaminoalkane Aspartic Protease Inhibitors | VITAE PHARMACEUTICAL, INC (US) | 2009-01-15 | — | — | US | disclosed |
| EP-1807078-A1 | DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| WO-2006042150-A1 | DIAMINOALKANE ASPARTIC PROTEASE INHIBITORS | VITAE PHARMACEUTICALS, INC. (US) | 2006-04-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100048636-A1 | Aspartic Protease Inhibitors | DNPEP, PEPD, SERPINB1 | ANPEP 7/4885ENPEP 9/4885GPR88 4464/4885 |
| US-20090018103-A1 | Diaminoalkane Aspartic Protease Inhibitors | DNPEP, PEPD, ACE | ANPEP 12/4885ENPEP 8/4885GPR88 1869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.